Swedbank AB Makes New $1.45 Million Investment in Vera Therapeutics, Inc. $VERA

Swedbank AB bought a new position in Vera Therapeutics, Inc. (NASDAQ:VERA) during the 3rd quarter, HoldingsChannel.com reports. The fund bought 50,000 shares of the company’s stock, valued at approximately $1,453,000.

Several other hedge funds have also made changes to their positions in the company. Quantbot Technologies LP acquired a new position in Vera Therapeutics in the 2nd quarter worth approximately $51,000. Quarry LP lifted its holdings in shares of Vera Therapeutics by 25.0% in the first quarter. Quarry LP now owns 2,500 shares of the company’s stock valued at $60,000 after purchasing an additional 500 shares in the last quarter. AlphaQuest LLC boosted its position in shares of Vera Therapeutics by 404.7% in the first quarter. AlphaQuest LLC now owns 4,007 shares of the company’s stock worth $96,000 after buying an additional 3,213 shares during the period. Virtus Investment Advisers LLC grew its holdings in shares of Vera Therapeutics by 14.8% during the second quarter. Virtus Investment Advisers LLC now owns 4,176 shares of the company’s stock valued at $98,000 after buying an additional 539 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its holdings in shares of Vera Therapeutics by 192.9% during the second quarter. Tower Research Capital LLC TRC now owns 4,186 shares of the company’s stock valued at $99,000 after buying an additional 2,757 shares in the last quarter. Hedge funds and other institutional investors own 99.21% of the company’s stock.

Insiders Place Their Bets

In other Vera Therapeutics news, Director Patrick G. Enright acquired 5,882 shares of Vera Therapeutics stock in a transaction that occurred on Thursday, December 11th. The stock was acquired at an average price of $42.50 per share, with a total value of $249,985.00. Following the purchase, the director owned 5,882 shares in the company, valued at approximately $249,985. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Joseph R. Young sold 15,000 shares of the company’s stock in a transaction on Tuesday, November 11th. The stock was sold at an average price of $29.06, for a total transaction of $435,900.00. Following the completion of the sale, the senior vice president owned 47,839 shares of the company’s stock, valued at $1,390,201.34. This represents a 23.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 16.30% of the stock is currently owned by company insiders.

Vera Therapeutics Stock Down 3.8%

Shares of Vera Therapeutics stock opened at $53.58 on Friday. The firm has a market cap of $3.43 billion, a price-to-earnings ratio of -13.43 and a beta of 1.21. The stock has a 50-day simple moving average of $36.26 and a 200-day simple moving average of $28.27. Vera Therapeutics, Inc. has a 52-week low of $18.53 and a 52-week high of $56.05. The company has a debt-to-equity ratio of 0.19, a current ratio of 12.21 and a quick ratio of 12.21.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($1.26) earnings per share for the quarter, missing the consensus estimate of ($1.20) by ($0.06). During the same quarter in the previous year, the company earned ($0.85) EPS. On average, equities research analysts expect that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. Bank of America raised their price objective on Vera Therapeutics from $48.00 to $66.00 and gave the stock a “buy” rating in a research report on Friday, December 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vera Therapeutics in a report on Wednesday, October 8th. Evercore ISI raised their price target on shares of Vera Therapeutics from $75.00 to $97.00 and gave the stock an “outperform” rating in a report on Monday, December 8th. Pivotal Research set a $73.00 price objective on shares of Vera Therapeutics in a research report on Friday, December 5th. Finally, Wedbush upped their price objective on shares of Vera Therapeutics from $23.00 to $33.00 and gave the company a “neutral” rating in a research note on Thursday, December 11th. Ten analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Vera Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $74.83.

Vera Therapeutics Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.